Health Care·Pharmaceuticals·$4.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.20 | N/A | -13.04% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.20 | N/A | -13.04% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concern over current performance but remains focused on future opportunities. They did not provide specific guidance for the upcoming quarters.
Management acknowledged challenges in meeting expectations.
They emphasized a focus on long-term growth despite short-term setbacks.
The earnings report indicates that Corcept Therapeutics faced challenges in meeting earnings expectations, leading to a 4.05% drop in stock price. Investors may be concerned about the company's ability to deliver consistent results. Without guidance, uncertainty remains about the company's future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ENTERPRISE PRODS PAR
May 2, 2022